Navigation Links
Edwards' Resilient Trial Demonstrates Statistically Superior Results for Treating Peripheral Arterial Disease in the Leg
Date:10/23/2007

self-expanding stent as an alternative for patients evaluating treatment options for SFA disease," said co-principal investigator John R. Laird, M.D., Medical Director of the Vascular Center at the University of California, Davis Medical Center. "Millions of patients suffering from PAD are in need of a clinically proven therapy that will improve their quality of life, allow them to be more active and walk without pain."

"We are very pleased with the 12-month results of The RESILIENT Trial, which provide clinicians with the highest level of clinical data available for a therapy to treat PAD patients less invasively," said Stuart L. Foster, Edwards' corporate vice president, Critical Care and Vascular.

The LifeStent self-expanding nitinol stent is a percutaneously-delivered flexible mesh tube that expands when deployed to prop open a diseased vessel and is specifically designed to withstand bending and twisting of the SFA. In 2004, Edwards initiated The RESILIENT Trial enrolling 246 patients at 25 sites, including 134 LifeStent self-expanding stent patients randomized against 72 balloon angioplasty patients.

The SFA is the major artery providing blood flow to the leg and extends behind the knee as the popliteal artery. This is a common area of blockage, or significant narrowing of the artery, in patients who suffer from atherosclerosis of the lower extremities, causing moderate to severe pain due to poor blood flow in the leg muscles. It is estimated that approximately 8 million Americans suffer from lower-extremity PAD, which affects mostly men and women older than 50 years. Without an effective treatment, PAD can develop into critical limb ischemia, a severe obstruction of the arteries with decreased blood flow to the lower extremities that may result in amputation.

Edwards is currently in discussions with the U.S. Food and Drug Administration (FDA) for premarket approval of its LifeStent system with an SFA indication.

About Edwards Li
'/>"/>

SOURCE Edwards Lifesciences Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
5. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
6. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
7. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
8. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
9. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Wash. , Dec. 19, 2014  Advanced ... stage development company engaged primarily in the development ... and therapeutic applications, today announced that a Life ... has been awarded for which AMIC is the ... State University (WSU) for the proposal titled "Optimized ...
(Date:12/19/2014)... CHAPEL HILL, N.C. , Dec. 19, 2014 ... marketplace, innovative consumer research and marketing communication tools ... rich and globally competitive – consequently consumers, desires, ... In this environment, market research groups across ... research and marketing communication tools. However, the adoption ...
(Date:12/19/2014)... Dec. 18, 2014 Somewhere between dropping five ... was forgotten. But Audicus , a next-generation hearing ... this new year. Hearing loss is the ... population, though it is often unaddressed. Forty-eight million Americans ... a hearing aid, mainly due to price. Hearing aids ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 3Study Uncovers New Tools and Techniques for Understanding Consumer Decision Making 2Audicus Will Help People Resolve to Hear Better in 2015 2
... /PRNewswire-FirstCall/ --,Genta Incorporated announced the presentation of ... its marketed product, Ganite(R) (gallium,nitrate injection), plus ... relapsed or refractory non-Hodgkin's,lymphoma (NHL). The data ... American Society of Clinical Oncology (ASCO) in ...
... in 35% of HER2-Positive Metastatic Breast,Cancer ... /PRNewswire-FirstCall/ -- Kosan,Biosciences Incorporated presented data ... that alvespimycin, its second-generation Hsp90,inhibitor, demonstrated ... with trastuzumab (Herceptin(R)) in,patients with refractory ...
Cached Medicine Technology:Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 2Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 3Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 4Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 5Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 2Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 3Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 4Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 5Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 6
(Date:12/21/2014)... 2014 Parker & Sons, Inc. a ... plumbing and other similar home contractor services announces a ... to its expert contracting services. The company is considered ... been serving Arizona for well over 40 years. Parker ... best in quality customer service to the residents and ...
(Date:12/21/2014)... CannabisClassifieds.com celebrates marijuana’s new legal place at the ... its kind, the site has provided its faithful users with ... running. It uniquely combines the benefits of platforms like ... to the masses. Assuring the potent herb’s followers it’s ... public approval. , Shane Chattin, Owner of Cannabis ...
(Date:12/20/2014)... December 21, 2014 MissyDress, a distinguished ... all prom lovers. The business has drastically cut prices ... dresses to everyone until Jan. 30, 2015. Many of ... sweetheart dresses, V-neck dresses, lace dresses, and more. , ... not there every day. Whether A-line princess prom dresses ...
(Date:12/20/2014)... print component of Healthy Aging is distributed within today’s ... and an estimated readership of 420,000. The digital component ... and across a network of top news sites and ... campaign, click here . , The publication features ... The Social. Lainey Lui, Melissa Grelo, Traci Melchor, ...
(Date:12/20/2014)... 2014 As Risperdal lawsuits ( ... U.S. courts, Bernstein Liebhard LLP notes the publication ... treated with the medication may experience elevated levels ... and lactation. The study, which appears in International ... who began treatment with risperidone, an antipsychotic medication ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 2Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 3Health News:CannabisClassifieds.com Maintains its “Craigslist for Cannabis” Standing with Website Re-launch 2Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4
... Funding Suspension After Trial Failures, WASHINGTON, ... piece today ( http://www.baltimoresun.com/news/opinion/oped/bal -,op.aidsvaccine23mar23,0,3426636.story), AIDS Healthcare ... HIV vaccine research funding and the,re- allocation ... and treatment strategies., Co-authored by Dr. ...
... can shield children from harm , , SATURDAY, March 22 ... which concludes Saturday, the Soap and Detergent Association offers ... , Parents and caregivers should: , Install child-safety ... chemicals and other poisons. Never assume a cabinet is ...
... But it,s not too late to protect yourself and ... News) -- News from the diabetes front seems to ... the disease, fueled by obesity and sedentary lifestyles, have ... affecting about 7 percent of the population. That,s an ...
... N.C., March 21 A CI head once noted ... it, but the only,time you realize you need it ... today,s marketing space, most companies need competitive,intelligence to effectively ... key insights are lacking that people begin to realize ...
... are small, the trend is worrisome, study says ... small, but worrisome number of facelift patients became ... MRSA, a new study reports. , About one ... developed the so-called "superbug" methicillin-resistant Staphylococcus aureus ...
... and genetic testing, study shows , , FRIDAY, March ... discuss a family,s cancer history has a major impact ... women at moderate risk for breast cancer, according to ... black women are less likely than white women ...
Cached Medicine News:Health News:HIV Vaccine Funding: 'Enough is Enough,' Says AHF in Baltimore Sun 2Health News:HIV Vaccine Funding: 'Enough is Enough,' Says AHF in Baltimore Sun 3Health News:HIV Vaccine Funding: 'Enough is Enough,' Says AHF in Baltimore Sun 4Health News:Poison Prevention Tips to Protect the Most Vulnerable 2Health News:Diabetes' Toll Continues to Grow 2Health News:Diabetes' Toll Continues to Grow 3Health News:Diabetes' Toll Continues to Grow 4Health News:New Research Uncovers How to Build and Maintain an Effective Competitive Intelligence Group 2Health News:Some Facelift Patients Infected With MRSA 'Superbug' 2Health News:Some Facelift Patients Infected With MRSA 'Superbug' 3Health News:Family Discussion Plays Role in Breast Cancer Awareness 2
... Implant (KGTI) system offers the latest technology ... MPJ. The implant system is anatomically designed ... ,The KGTI is the most advanced reconstructive ... on the market today. The system consists ...
... Nerve Electrodes provide direct cranial nerve ... patented circumferential design provides sensitive contact ... stable real-time recordings. This unique approach ... the removal of acoustic neuromas, microvascular ...
... Ad-Techs Model CMU Cortical Mapping Unit ... of recording EEGs from exposed cortex during ... each electrode plate can be positioned independently ... clamp provides two alternative mounting locations and ...
An ambulatory recorder can help the patient be more comfortable and at ease as well as increasing an EEG laboratory's recording capacity....
Medicine Products: